Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats

Pharmacology Biochemistry and Behavior

Volumn 78, Issue 4, 2004, Pages 683-689

  Yamauchi, Miki ^a   Tatebayashi, Tomoko ^a   Nagase, Kinuko ^a   Kojima, Maho ^a   Imanishi, Taiichiro ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

5 HT2C receptor; Anxiety disorders; Fluvoxamine; Locomotor activity; m Chlorophenylpiperazine; Paroxetine; Rat; Selective serotonin re uptake inhibitor

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; LOCOMOTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUVOXAMINE; HYPOKINESIA; MALE; MOTOR ACTIVITY; PAROXETINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 3843129755     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.05.003     Document Type: Article

References (39)

1. Arnt J., Hyttel J., Overø K.F. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol. J. Pharmacol. Pharm. 36:1984;221-230
2. 1A antagonists. Trends Neurosci. 19:1996;378-383
3. 1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 4:2001;399-408
4. 2 receptor subtypes: a family re-united? Trends Pharmacol. Sci. 16:1995;105-110
5. Bel N., Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur. J. Pharmacol. 229:1992;101-103
6. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15:1993;243-245
7. Bosker F.J., Klompmakers A.A., Westenberg H.G.M. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology. 34:1995;501-508
8. 1A receptor antagonist, WAY 100635, in the rat. Neuropharmacology. 39:2000;1222-1236
9. 2C receptors. Neuropharmacology. 39:2000;1114-1117
10. 1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol. 10:1996;16-27
11. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115:1995;1064-1070
12. 2B receptors. Behav. Pharmacol. 12:2001;613-620
13. 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem. 62:1994;2262-2268
14. Gurevich I., Englander M.T., Adlersberg M., Siegal N.B., Schmauss C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J. Neurosci. 22:2002;10529-10532
15. Hollander E., DeCaria C., Gully R., Nitescu A., Suckow R.F., Gorman J.M., et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. 36:1991;1-17
16. Hollander E., Kwon J., Weiller F., Cohen L., Stein D.J., DeCaria C., et al. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Res. 79:1998;213-217
17. Ishikane T., Koyama T., Matsubara S., Odagaki Y., Matsubara R., Yamashita I. Pharmacological properties of a new antidepressant, fluvoxamine (SME3110): effects on extracellular levels of monoamine in vivo and monoaminergic receptors in rat brain. (in Japanese) Jpn. J. Neuropsychopharmacol. 16:1994;37-43
18. C receptor. Science. 241:1988;558-564
19. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry. 30:1991;1139-1166
20. Kahn R.S., Wetzler S., van Praag H.M., Asnis G.M., Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res. 25:1988a;101-104
21. Kahn R.S., Asnis G.M., Wetzler S., van Praag H.M. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology. 96:1988b;360-364
22. Kennedy A.J., Gibson E.L., O'Connell M.T., Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology. 113:1993;262-268
23. 2B receptor function. Neuropharmacology. 33:1994;1581-1588
24. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620
25. Kent J.M., Coplan J.D., Gorman J.M. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry. 44:1998;812-824
26. Klaassen T., Riedel W.J., van Praag H.M., Menheere P.P.C.A., Griez E. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression. Psychiatry Res. 113:2002;29-40
27. Maj J., Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J. Neural Transm.: Gen. Sect. 88:1992;143-156
28. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol. Biochem. Behav. 71:2002;615-625
29. Masand P.S., Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatr. 7:1997;69-84
30. Nutt D.J., Forshall S., Bell C., Rich A., Sandford J., Nash J., et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 9(Suppl. 3):1999;S81-S86
31. Pigott T.A., Zohar J., Hill J.L., Bernstein S.E., Grover G.N., Zohar-Kadouch R.C., et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol. Psychiatry. 29:1991;418-426
32. 1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;177-183
33. Sánchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19:1999;467-489
34. Sanders-Bush E., Breeding M., Knoth K., Tsutsumi M. Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacology. 99:1989;64-69
35. 2 receptors: molecular and genomic diversity. Mol. Interv. 3:2003;319-330
36. Smith T.M., Suckow R.F. Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology. 24:1985;1067-1071
37. Tao R., Ma Z., Auerbach S.B. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J. Pharmacol. Exp. Ther. 294:2000;571-579
38. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch. Gen. Psychiatry. 44:1987;946-951
39. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch. Gen. Psychiatry. 45:1988;167-172